Sigachi Industries Q4 FY26 Financials

Sigachi Industries reported Q4 FY26 operating income of ₹121.89 crore and a net profit of ₹7.6 crore. The company’s EBITDA stood at ₹15.4 crore with a margin of 12.63%.

Reader Takeaway: Capacity expansion plans offer growth; Hyderabad plant legal issues remain a concern.

What just happened

Sigachi Industries announced its financial results for the fourth quarter of fiscal year 2026. Total operating income was ₹121.89 crore, with Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) at ₹15.4 crore, resulting in an EBITDA margin of 12.63%. Net Profit After Tax (PAT) for the quarter was ₹7.6 crore, with a PAT margin of 6.23%.

The company’s revenue streams were primarily from Microcrystalline Cellulose (MCC) contributing ₹85.33 crore, followed by Operations & Maintenance (O&M) at ₹14.63 crore, and Active Pharmaceutical Ingredients (API) at ₹17.06 crore.

Why this matters

The results reflect Sigachi Industries' performance as it navigates operational challenges and pursues strategic expansion. The focus on capacity expansion, particularly at Dahej, aims to drive future revenue growth and improve profitability. The company has also provided for the Hyderabad plant incident and is expecting insurance claims.

The backstory

Sigachi Industries has been working towards margin normalization after an incident at its Hyderabad plant, which is currently sub judice. The company has made full provisions for this shutdown. Meanwhile, strategic capacity expansion projects are underway to bolster future revenue streams and market position.

What changes now

With the Q4 FY26 results, Sigachi Industries has set clear financial targets for FY27, projecting revenue between ₹650–675 crore and EBITDA margins of 18–20%. The company is actively pursuing insurance claims totaling approximately ₹70 crore to support its financial position. Working capital debt stood at ₹145 crore as of May 30, 2026, with plans to reduce it.

Risks to watch

Investors will be watching for Sigachi Industries' ability to achieve its guided EBITDA margins of 18-20% by FY27/FY28, indicating a successful recovery. The ongoing legal dispute over the Hyderabad facility remains a point of concern, although management has accounted for potential losses.

Peer comparison

While specific peer financial data for the same period is not provided in the filing, Sigachi Industries' focus on cellulose-based excipients places it within the pharmaceutical excipients and specialty chemicals sector. Companies in this space typically compete on product quality, regulatory compliance, and production efficiency.

Context metrics (time-bound)

• Q4 FY26: Total Operating Income ₹121.89 crore, EBITDA ₹15.4 crore, Net Profit ₹7.6 crore.
• FY27 Guidance: Revenue ₹650–675 crore, EBITDA Margins 18–20%.
• Dahej Expansion: 12,000 MT MCC capacity by Q4 FY27; 1,800-ton CCS facility by Q1 FY28.
• Insurance Claims: Expected ₹70 crore.
• Working Capital Debt: ₹145 crore (as of May 30, 2026).

What to track next

Investors should monitor the progress of the Dahej capacity expansions and their commissioning timelines. The realization of insurance claims and the company's efforts to reduce working capital debt will be key financial indicators. Additionally, tracking the achievement of projected revenue and EBITDA margins for FY27 will be crucial for assessing the company's recovery and growth trajectory.